Biomarkers for neurodegenerative diseases are needed to improve the diagnostic workup in
the clinic but also to facilitate the development and monitoring of effective disease-modifying …

Introduction Global estimates on numbers of persons in early stages of Alzheimer's disease
(AD), including prodromal and preclinical, are lacking, yet are needed to inform policy …

Importance Tau positron emission tomography (PET) tracers have proven useful for the
differential diagnosis of dementia, but their utility for predicting cognitive change is unclear …

For optimal design of anti-amyloid-β (Aβ) and anti-tau clinical trials, we need to better
understand the pathophysiological cascade of Aβ-and tau-related processes. Therefore, we …

In Alzheimer's disease (AD), younger symptom onset is associated with accelerated disease
progression and tau spreading, yet the mechanisms underlying faster disease manifestation …

PET, CSF and plasma biomarkers of tau pathology may be differentially associated with
Alzheimer's disease (AD)‐related demographic, cognitive, genetic and neuroimaging …

Different tau biomarkers become abnormal at different stages of Alzheimer's disease, with
CSF phospho-tau typically becoming elevated at subthreshold levels of tau-PET binding. To …

Healthy aging is an ambitious aspiration for humans, but neurodegenerative disorders, such
as Alzheimer's disease (AD), strongly affect quality of life. Using an integrated omics …

Deposition of amyloid and tau pathology can be quantified in vivo using positron emission
tomography (PET). Accurate longitudinal measurements of accumulation from these images …

Importance Longitudinal tau positron emission tomography (PET) is a relevant outcome in
clinical trials evaluating disease-modifying therapies in Alzheimer disease (AD). A key …